Abstracts tagged "Vaccination"

Abstract Number: 1086 • ACR Convergence 2021
Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Inflammatory Biomarkers
Mark Rudolph, Anja Kammensheidt and Roberta Alexander, Exagen Inc., Vista, CA
Background/Purpose: SARS-CoV-2 infection can lead to severe inflammation including increased complement activation (Ma, Kulkarni 2021) and the production of several proinflammatory cytokines. The rapid deployment…
Abstract Number: 1420 • ACR Convergence 2021
Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
Peter Izmirly¹, Mimi Kim², Marie Samanovic-Golden³, Ruth Fernandez Ruiz⁴, Sharon Ohana³, Alexis Engel⁵, Kristina Deonaraine¹, Mala Masson⁴, Xianhong Xie⁶, Amber Cornelius⁴, Ramin Herati⁴, Rebecca Haberman⁴, Jose Scher¹, Allison Guttmann³, Rebecca Blank⁷, Ben Plotz³, Mayce Haj-Ali⁴, Brittany Banbury³, Sara Stream⁸, Ghadeer Hasan³, Gary Ho³, Paula Rackoff⁷, Ashira Blazer³, H. Michael Belmont³, Amit Saxena³, Mark Mulligan⁴, Robert Clancy⁴ and Jill Buyon³, ¹New York University School of Medicine, New York, NY, ²Albert Einstein College of Medicine, Larchmont, NY, ³NYU School of Medicine, New York, NY, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New Yok, NY, ⁶Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, ⁷New York University, New York, NY, ⁸NYU Langone Health, New York, NY
Background/Purpose: Since the Phase 3 clinical studies of all three COVID-19 vaccines excluded patients on immunosuppressants or immune-modifying drugs within 6 months of enrollment, data…
Abstract Number: 1421 • ACR Convergence 2021
Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemic Lupus Erythematosus: The International VACOLUP Study
Renaud Felten¹, Lou KAWKA², Maxime DUBOIS², Manuel Ugarte-Gil³, Yurilis Fuentes-Silva⁴, Matteo PIGA⁵ and Laurent Arnaud¹, ¹Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ²National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France, ³Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴Division of Rheumatology, Complejo Hospitalario Universitario Ruiz y Páez, Universidad de Oriente, Ciudad Bolívar, Centro Nacional de Enfermedades Reumáticas, Ciudad Bolívar, Venezuela, ⁵Department of Medical Science and Public Health, University of Cagliari, Cagliary, Italy
Background/Purpose: Both efficacy and safety data regarding COVID vaccines in systemic lupus erythematosus (SLE) are lacking. We conducted the international Vaccination Against COvid in systemic…
Abstract Number: 1535 • ACR Convergence 2021
Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination
Rebecca Blank¹, Rebecca Haberman², Rochelle Castillo², marie Samanovic³, Parvathy Vasudevanpillai Girija⁴, Paula Rackoff¹, Gary Solomon⁵, Natalie Azar⁶, Pamela Rosenthal⁷, Peter Izmirly⁴, Jonathan Samuels⁸, Brian Golden⁹, Soumya Reddy⁷, Steven B. Abramson⁴, Mark Mulligan³ and Jose Scher⁴, ¹New York University, New York, NY, ²NYU Langone Health, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Langone School of Medicine, Hartsdale, NY, ⁶NYU Langone, New York, NY, ⁷NYU School of Medicine, New York, NY, ⁸NYU Langone, Rye Brook, NY, ⁹NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Recent studies have shown high rates of autoantibody production in patients hospitalized with COVID-19, including antinuclear antibodies (ANA) and antibodies associated with antiphospholipid syndrome.…
Abstract Number: 1536 • ACR Convergence 2021
Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease
Sara Tedeschi¹, Jack Ellrodt¹, Jacklyn Stratton¹, Leah Santacroce¹, Paulette Chandler¹, Ellen Gravallese² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Vaccination against preventable infections is widely recommended for patients with systemic rheumatic disease. The COVID-19 pandemic has highlighted variability in attitudes toward vaccination, particularly…
Abstract Number: 1546 • ACR Convergence 2021
Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients
Ingrid Jyssum¹, Anne Therese Tveter¹, Fridtjof Lund-Johansen², Ludvig Munthe², Sella Provan¹, Kristin Jørgensen³, Gunnveig Grødeland², Grete Kro², David Warren², Joseph Sexton¹, Tore Kvien¹, Siri Mjaaland⁴, Espen Haavardsholm¹, John Torgils Vaage², Silje Watterdal Syversen¹ and Guro Goll¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Oslo University Hospital, Oslo, Norway, ³Akershus University Hospital, Lørenskog, Norway, ⁴Norwegian Institute of Public Health, Oslo, Norway
Background/Purpose: To assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive medication for inflammatory arthritis.Methods: Adult patients…
Abstract Number: 803 • 2019 ACR/ARP Annual Meeting
Hepatitis a Virus Vaccination in Autoinflammatory Diseases Under Canakinumab and Tocilizumab Treatment
Kenan Barut ¹, Amra Adrovic ², Sezgin Sahin ³, Mehmet Yıldız ², Oya Koker ², Gamze Yalcin ², Omer Faruk Beser ⁴, Bekir Kocazeybek ⁵, Pelin Yuksel ⁵ and Ozgur Kasapcopur⁶, ¹Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, İstanbul, Istanbul, Turkey, ²Department of Pediatric Rheumatology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, ³Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ⁴Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Istanbul, Turkey, ⁵Department of Microbiology, Istanbul University Cerrahpasa, Istanbul, Istanbul, Turkey, ⁶Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa, Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Autoimmune, autoinflammatory mechanism and drugs used in treatment increase the risk of liver disease in patients with chronic rheumatic diseases. Hepatitis A vaccine is…
Abstract Number: 1804 • 2019 ACR/ARP Annual Meeting
Safety of the Zoster Vaccine Recombinant, Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center’s Experience with 400 Patients
Emma Stevens¹, Michael Weinblatt ¹, Elena Massarotti ², Frances Griffin ¹, Srinivas Emani ¹ and Sonali Desai ³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital Assistant Professor of Medicine, Harvard Medical S, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) and other systemic diseases (SD) are at an increased risk of developing Herpes Zoster (HZ) due to either the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].